Methenamine Hippurate Eql Pharma (Methenamine Hippurate)

In acidic urine (pH below 6), Methenamine Hippurate is hydrolysed to formaldehyde and ammonia. Formaldehyde acts as a broad‑spectrum antibacterial agent, inhibiting the growth of common urinary pathogens and thereby reducing bacterial colonisation in the bladder.

The prescribed dose is determined by the treating physician based on the patient’s renal function, urinary pH and clinical history. Dosage forms are typically oral tablets taken with adequate fluid, and the exact regimen should follow the prescriber’s instructions.

Safety data are limited and the pregnancy category is unknown. Because formaldehyde is generated in the urine, clinicians usually avoid routine use during pregnancy and lactation unless the benefit clearly outweighs potential risk. Consultation with a healthcare professional is essential.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Unlike systemic antibiotics, Methenamine Hippurate is activated locally in acidic urine to release formaldehyde, reducing the risk of bacterial resistance. Other agents such as nitrofurantoin act systemically and have broader antimicrobial spectra, but may carry higher risks of systemic side effects.

Store at room temperature, below 25 °C, in the original packaging. Protect from moisture and direct sunlight. Keep the container tightly closed and out of reach of children. Do not refrigerate or freeze the product.

The medication is taken orally, usually as a tablet, with a full glass of water. It should be taken on an empty stomach or as directed by the prescriber to ensure optimal urinary acidification. Adequate hydration is recommended to maintain urine flow.

Serious but rare adverse events include severe allergic reactions such as anaphylaxis, hematuria, Stevens‑Johnson syndrome, and significant renal or hepatic impairment. Immediate medical attention is required if symptoms like rash, swelling, difficulty breathing, or blood in the urine develop.

Patients with known hypersensitivity to methenamine or its metabolites, those with severe renal insufficiency, individuals whose urine cannot be acidified, and persons with an active urinary tract infection requiring immediate antibiotic therapy should avoid this drug unless specifically directed by a physician.